Zealand Pharma — November 2022

[exitnu]

Tydeligvis en glitch - desværre.

[exitnu]

Luk i 189,50 & -1,66%. God aften

[ProinvestorNEWS]

Zealand Pharma Q3: Omsætning dykker og underskud vokser https://www.proinvestor.com/investornyt/903219/zealand-pharma-q3-omsaetning-dykker-og-underskud-vokser

[Helge_LarsenPI-redaktør]

Godmorgen

[Stroka]

God morgen

[exitnu]

God morgen

[ungeee]

22.21 - ikke for at lave ballade, men hvilken planet er du på? Eller er du ude på sjov

[exitnu]

"Jeg kan, på ingen måde, se at selskabet skulle være en investering værd"

JA der er fx sket alt for lidt i Q3:

[exitnu]

Announced positive topline results from the pivotal Phase 3 EASE-1 trial of glepaglutide, a long-acting GLP-2 analogue designed for subcutaneous delivery via auto-injector, in patients with short bowel syndrome (SBS).

[exitnu]

Reported results from the Boehringer Ingelheim-sponsored Phase 2 clinical trial of BI 456906, a glucagon receptor/glucagon-like peptide-1 receptor (GCGR/GLP-1R) dual agonist, in patients with type 2 diabetes (T2D) at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD).

[exitnu]

Presented results from the Phase 3 clinical trial of dasiglucagon in congenital hyperinsulinism (CHI) at the 60th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE).

[exitnu]

Completed dose escalation in the ongoing Phase 1a single ascending dose (SAD) trial of ZP8396, a long-acting amylin analogue.

[exitnu]

Announced a global license and development agreement with Novo Nordisk to commercialize ZEGALOGUE (dasiglucagon) for injection.

[exitnu]

Personligt synes jeg at Zealand Pharma har overpræsteret. Alt går deres/vores vej ...

[exitnu]

@Pensionisten - gider du venligst uddybe - tak!

[exitnu]

Plus disse fire begivenheder:

Presented preclinical data at the Annual Meeting of the Obesity Society (Obesity Week). Reported results from the Boehringer Ingelheim-sponsored Phase 2 clinical trial of BI 456906 (GCGR/GLP-1R) in patients with T2D at Obesity Week. Phase 2 trial of BI 456906 in patients with non-alcoholic steatohepatitis (NASH). Received gross proceeds of DKK 786 million from a directed issue and private placement.

[ProinvestorNEWS]

[Svingtraderen]

morning i klubben:)

[Svingtraderen]

22:21 synes det er væltet ind med nyheder i min Q3 - aktien er steget fra 75 til 190. Er op ca 30% i år mens markedet er ned 20%. Kan ikke liiige se hvad der mangler:)

[Svingtraderen]

og tak @exitnu